Financial Performance - The company's revenue decreased by 18.5% from RMB 16,284 million in 2024H1 to RMB 13,273 million in 2025H1[35] - Gross profit decreased by 25.3% from RMB 11,655 million in 2024H1 to RMB 8,710 million in 2025H1[35] - Gross profit margin decreased by 6.0 percentage points from 71.6% in 2024H1 to 65.6% in 2025H1[35] - Reported profit attributable to shareholders of the Company decreased by 15.6% from RMB 3,020 million in 2024H1 to RMB 2,548 million in 2025H1[35] - Underlying profit attributable to shareholders of the Company decreased by 27.9% from RMB 3,217 million in 2024H1 to RMB 2,320 million in 2025H1[35] - Revenue from finished drugs decreased by 24.4% from RMB 13,549 million in 2024H1 to RMB 10,248 million in 2025H1[36] - Revenue from bulk vitamin C increased by 21.6% from RMB 984 million in 2024H1 to RMB 1,196 million in 2025H1[36] - Revenue from nervous system therapeutics decreased by 28.3% from RMB 5,236 million in 2024H1 to RMB 3,755 million in 2025H1[37] - Revenue from oncology therapeutics decreased significantly by 60.8% from RMB 2,683 million in 2024H1 to RMB 1,051 million in 2025H1[37] R&D and Pipeline - The company has 5 R&D centers located in China & the U S [6,99] - The company has approximately 200 innovative drugs and new formulations [6,99] - R&D expenses increased by 5.5% from RMB 2,542 million in 2024H1 to RMB 2,683 million in 2025H1[35] Business Development - The company has license-out agreements including a potential milestone payment of $105 billion for GLP-1, $522 billion for ROR1 ADC, $1955 billion for Irinotecan Liposome Injection, and $1225 billion for strategic collaboration [116]

ck Code : 1093) 2025 Interim Results Presentation Aug. 2025 ININI China's Leading Innovative Pharmaceutical Enterprise R&D Capabilities 00 5 capacity of 250,000L R&D centers located in R&D platforms China & the U.S. 201010 + - 2401 Innovative drugs and R&D professionals new formulations Manufacturing Capabilities Commercialization Capabilities 2 10+ Production bases for pharmaceutical products Nano formulation production capacity of 20M doses/year; Biologics fermentation Chemical drugs production capacity o ...

Core Viewpoint - The announcement highlights that JMT101, developed by the company, has received breakthrough therapy designation from the National Medical Products Administration of China for treating advanced colorectal cancer that has failed second-line or higher standard treatments [1][3]. Group 1: Clinical Significance - Colorectal cancer is the third most common cancer globally, with 517,000 new cases and 240,000 deaths reported in China in 2022, ranking second and fourth respectively in new cases and deaths from malignant tumors [1]. - Current standard treatment for advanced colorectal cancer that has failed second-line or higher therapies has a low objective response rate (ORR) of ≤5% and a median progression-free survival (mPFS) of approximately 3 months, indicating a significant unmet clinical need [1]. Group 2: JMT101 Characteristics - JMT101 is a recombinant humanized monoclonal antibody with a novel molecular structure, exhibiting antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [2]. - JMT101 shows significantly higher target affinity compared to similar products and reduces immunogenicity and infusion reactions [2]. Group 3: Clinical Trial Results - In a randomized, controlled, open-label Phase II study, the combination of JMT101 and irinotecan demonstrated superior ORR, disease control rate (DCR), and mPFS compared to the control group, with an mPFS of 7.4 months versus 2.9 months for the control [2]. - The study results will be presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting [2]. Group 4: Future Prospects - JMT101 has shown preliminary breakthrough efficacy and good safety in clinical studies, indicating a potential to become the standard treatment for post-line colorectal cancer [3]. - The company is advancing JMT101 in a pivotal Phase III clinical trial for this indication and is also conducting multiple Phase II and III clinical studies for other solid tumors, including lung cancer and nasopharyngeal carcinoma [3]. - The breakthrough therapy designation is expected to expedite the development process of JMT101 based on its promising efficacy and safety data [3].